There is no funding for this project: applications can only be accepted from self-funded candidates
1. Ioannou N, Seddon A, Dalgleish A, Mackintosh D and Modjtahedi H (2012). Expression pattern and targeting of targeting of HER family members and IGF-IR in pancreatic cancer. Frontiers in Bioscience 17:2698-724.
2. Ioannou N, Seddon AM, Dalgleish A2, Mackintosh D, Solca F, and Modjtahedi H (2016). Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International Journal of Oncology 48(3), 908-918.
3. Ioannou I, Seddon AM, Dalgleish A, Mackintosh D and Modjtahedi H (2013). Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 31;13:4. doi: 10.1186/1471-2407-13-41.
4. Ioannou N, Dalgleish A G, Seddon A M, Mackintosh D, Guertler U, Solca F and Modjtahedi H (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British Journal of Cancer 105:1554–1562.
FTE Category A staff submitted: 17.22
Research output data provided by the Research Excellence Framework (REF)Click here to see the results for all UK universities